New weight-loss drugs: what 6 drugmakers are testing
Article excerpt
Highlighted: the sentence this signal was extracted from
Wegovy and Zepbound became blockbuster treatments, and drugmakers are now placing bets on what comes after them. The new weight-loss drugs moving through company pipelines range from a compound known only by its code name to a candidate that already carries a brand name. Those bets come from Novo Nordisk, Eli Lilly $LLY and other drugmakers. Reuters surveyed the field in a roundup of weight-loss treatments in development. That roundup covers far more drugmakers than this article does. The six companies here are a selection drawn from it. They are not a ranking, and their order says nothing about which drug is likely to succeed. Novo Nordisk is developing CagriSema and amycretin. Eli Lilly 's lineup includes Foundayo, retatrutide and EloraTZP. Pfizer $PFE is working on a candidate identified so far only by its code name, PF-3944. Roche has enicepatide, a dual-acting drug it gained through its $2.7 billion purchase of U.S. biotech Carmot Therapeutics in 2023. Amgen $AMGN is testing MariTide in six late-stage trials covering obesity and related conditions. Viking Therapeutics is developing VK2735, which comes in two forms that share one name. The numbers in the slides that follow need careful reading. Each trial result here was reported by the company behind the drug. The trials also differ in who took part, how long they lasted and what stage of testing they reached. A...
Keep reading with a free account
The rest of this article, and every signal for Novo Nordisk, is in your free account.
